1-(3-甲氧基-4-甲基苯基)乙酮 | 3556-81-8

• 物质功能分类: 有机原料 - 酮类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(3-甲氧基-4-甲基苯基)乙酮
• 英文名称: 3-methoxy-4-methylacetophenone
• 英文别名: 1-(3-methoxy-4-methylphenyl)ethan-1-one；3-Methoxy-4-methylacetophenon；1-(3-Methoxy-4-methylphenyl)ethanone
• CAS: 3556-81-8
• 化学式: C₁₀H₁₂O₂
• 分子量: 164.204
• InChiKey: SZYKDYIBUSNYRS-UHFFFAOYSA-N

物化性质

• 保留指数：
  1601

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  1-(3-甲氧基-4-甲基苯基)乙酮 在 dimethyl sulfide borane 、 对甲苯磺酸 、 对苯二酚 作用下， 以 四氢呋喃 、 乙醚 、 苯 为溶剂， 反应 6.5h， 生成 rac-2-(3-methoxy-4-methylphenyl)propan-1-ol
  参考文献：
  名称：

  Lipase-mediated resolution of substituted 2-aryl-propanols: application to the enantioselective synthesis of phenolic sesquiterpenes

  摘要：

  A comprehensive study of the lipase-mediated resolution of substituted 2-aryl-propanols is reported. The latter alcohols were submitted to the irreversible acetylation catalyzed either by PPL, CRL, or lipase PS. The enantioselectivity of these transformations was dependent on the type of lipase used. The type of substituents and particularly their position on the aromatic ring strongly affected the selectivity of the reaction. The experiments described prove that PPL is the more versatile lipase catalyzing the acetylation with an enantiomeric ratio (E) value that ranges from 1 up to 144, depending on the substrate used. Conversely, the same transformations were catalyzed by CRL and lipase PS with an enantiomeric ratio value, which is always less than 5. The remarkable behavior of PPL was exploited in the large scale resolution of some substituted 2-aryl-propanols whose enantiomeric forms are relevant building blocks in the enantioselective synthesis of phenolic sesquiterpenes. By these means, the synthesis of (S)-turmeronol B and the formal syntheses of (R)-curcumene, (R)-curcuphenol, (R)-xanthorrhizol, and (R)-curcuhydroquinone were accomplished. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2011.03.012
• 作为产物：
  描述：

  3-甲氧基-4-甲基苯甲酸 在 manganese(IV) oxide 、 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 氯仿 为溶剂， 反应 8.0h， 生成 1-(3-甲氧基-4-甲基苯基)乙酮
  参考文献：
  名称：

  贝克酵母介导的双倍半硼烷倍半萜（+）-姜酚，（+）-黄姜酚，（-）-姜酚和（+）-姜氢醌的对映选择性合成

  摘要：

  发酵面包酵母转化不饱和酵母 醛类 5a–c进入饱和状态酒类 分别为6a–c。吸附在非极性树脂上的底物的微生物饱和度以高化学收率进行，并且在（S）-（+）异构体的形成过程中显示出完全的对映选择性。Enantiopure 6a–c是通用的手性构件，可用于合成比沙泊烷 倍半萜。它们的有用性示于（制备小号） - （+） - curcuphenol，（小号） - （+） - xanthorrhizol，（小号） - （ - ） - curcuquinone和（小号） - （+） - curcuhydroquinone。

  DOI：

  10.1039/b006141g

文献信息

• [EN] PYRIMIDINE, PYRIDINE AND TRIAZINE DERIVATIVES AS MAXI-K CHANNEL OPENERS.<br/>[FR] DÉRIVÉS DE PYRIMIDINE, PYRIDINE ET TRIAZINE EN TANT QU'OUVREURS DE CANAUX MAXI-K
  申请人：MITSUBISHI TANABE PHARMA CORP

  公开号：WO2009125870A1

  公开（公告）日：2009-10-15

  A compound of formula (A); wherein ring A is an aromatic ring or a heteroaromatic ring; R1 is independently halogen, cyano, etc., each of X1, X2 and X3 is CR2 or nitrogen, R2 is independently hydrogen, etc., n is 0, 1, 2, 3 or 4; -D-Y is -O-CH2COOH, etc, and G is a substituted amino, a substituted heterocyclic group, etc, or a pharmaceutical acceptable salt thereof, has activities of opening BK channels.

  化合物的结构式（A）；其中环A是芳香环或杂芳环；R1独立地是卤素、氰基等；X1、X2和X3中的每一个是CR2或氮，R2独立地是氢等；n为0、1、2、3或4；-D-Y是-O-CH2COOH等；G是取代氨基、取代杂环基等，或其药用可接受盐，具有开放BK通道的活性。
• Design, Conformation, and Crystallography of 2-Naphthyl Phenyl Ethers as Potent Anti-HIV Agents
  作者：Won-Gil Lee、Albert H. Chan、Krasimir A. Spasov、Karen S. Anderson、William L. Jorgensen

  DOI：10.1021/acsmedchemlett.6b00390

  日期：2016.12.8

  7-cyano-2-naphthyl substituent are reported as non-nucleoside inhibitors of HIV-1 reverse transcriptase (NNRTIs). Many of the compounds have 1–10 nM potencies toward wild-type HIV-1. An interesting conformational effect allows two unique conformers for the naphthyl group in complexes with HIV-RT. X-ray crystal structures for 4a and 4f illustrate the alternatives.

  据报道，掺有7-氰基-2-萘基取代基的邻苯二酚二醚是HIV-1逆转录酶（NNRTIs）的非核苷抑制剂。许多化合物对野生型HIV-1的效价为1-10 nM。一个有趣的构象效应使得与HIV-RT形成复合物的萘基具有两个独特的构象体。4a和4f的X射线晶体结构说明了替代方案。
• CATALYST COMPOUNDS
  申请人：THE UNIVERSITY OF LIVERPOOL

  公开号：US20150080592A1

  公开（公告）日：2015-03-19

  The present invention relates to an iridium-based catalyst compound for hydrogenating reducible moieties, especially imines and iminiums, the catalyst compounds being defined by the formulas: where ring B is either itself polycyclic, or ring B together with R is polycyclic. The catalysts of the invention are particularly effective in reductive amination procedures 10 which involve the in situ generation of the imine or iminium under reductive hydrogenative conditions.

  本发明涉及一种基于铱的催化剂化合物，用于氢化可还原基团，特别是亚胺和亚胺盐，所述催化剂化合物由以下公式定义：其中环B要么本身是多环的，要么环B与R一起是多环的。本发明的催化剂在涉及在还原氢化条件下原位生成亚胺或亚胺盐的还原胺化过程中特别有效。
• [EN] INHIBITORS OF NHE-MEDIATED ANTIPORT<br/>[FR] INHIBITEURS D'ANTIPORT À MÉDIATION PAR NHE
  申请人：ARDELYX INC

  公开号：WO2018129557A1

  公开（公告）日：2018-07-12

  The present disclosure is directed to compounds (Ι') and to their use in methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds (Ι') and their use in methods for the treatment of hypertension. The present disclosure is also directed to compounds (Ι') and to their use in methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

  本公开涉及化合物(Ι')及其在治疗与液体潴留或盐超负荷相关的疾病的方法中的用途，例如心力衰竭（尤其是充血性心力衰竭）、慢性肾病、终末期肾病、肝病以及过氧化物酶体增殖物激活受体（PPAR）gamma激动剂引起的液体潴留。本公开还涉及化合物(Ι')及其在治疗高血压的方法中的用途。本公开还涉及化合物(Ι')及其在治疗胃肠道疾病的方法中的用途，包括治疗或减少与胃肠道疾病相关的疼痛。
• 8-Substituted isoquinoline derivative and the use thereof
  申请人：Kaneko Shunsuke

  公开号：US20100261701A1

  公开（公告）日：2010-10-14

  The present invention relates to a compound represented by the following formula (1): wherein D 1 , A 1 , D 2 , R 1 , D 3 , and R 2 each have the same meaning as defined in the present specification or a salt thereof. The compound represented by the formula (1) or a salt thereof has an IKKβ inhibiting activity and the like and is useful for the prevention and/or treatment of IKKβ-associated diseases or symptoms and the like.

  本发明涉及一种由以下式（1）表示的化合物： 其中D1，A1，D2，R1，D3和R2分别具有与本说明书中定义的相同含义或其盐。由式（1）表示的化合物或其盐具有IKKβ抑制活性等，对于预防和/或治疗IKKβ相关疾病或症状等方面是有用的。